GLP-1 RAs in Patients With Polycystic Ovary Syndrome (PCOS)

NCT04876027 on ClinicalTrials.gov · last registry update 2022-08-04

Finished 30 April 2022, after enrolling 68 people. Primary outcome, as filed: the change in visceral adipose tissue. dulaglutide is approved in the US, but not for pcos — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P4
Drug: dulaglutide
Trulicity
Sponsor: Shanghai 10th People's Hospital
Sponsor type: Other
Enrollment: 68
Started: 2021-05-15
Primary completion: 2022-04-30 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

the change in visceral adipose tissue

Conditions studied

Polycystic Ovary Syndrome

Every field above is taken directly from the registry record. See all detected changes across the class, or the dulaglutide page for this molecule’s full trial and approval history.